Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma ; volume:36 ; number:10 ; day:7 ; month:8 ; year:2019 ; pages:2679-2696 ; date:10.2019
Advances in therapy ; 36, Heft 10 (7.8.2019), 2679-2696, 10.2019
- Urheber
-
Ishizawa, Kenichi
Yanai, Tomoko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-019-01046-w
- URN
-
urn:nbn:de:101:1-2020021310524663725100
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ishizawa, Kenichi
- Yanai, Tomoko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Primary Cutaneous Anaplastic Large-Cell Lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Migration properties distinguish tumor cells of classical hodgkin lymphoma from anaplastic large cell lymphoma cells
Anaplastic large cell lymphoma ALK negative vs. peripheral T cell lymphoma (NOS) - diagnostic dilemma
Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma
T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma
Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with extranodal involvement of the thigh muscle: a case report
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Primary Cutaneous Anaplastic Large-Cell Lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Migration properties distinguish tumor cells of classical hodgkin lymphoma from anaplastic large cell lymphoma cells
Anaplastic large cell lymphoma ALK negative vs. peripheral T cell lymphoma (NOS) - diagnostic dilemma
Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma
T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma
Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with extranodal involvement of the thigh muscle: a case report
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Primary Cutaneous Anaplastic Large-Cell Lymphoma
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Migration properties distinguish tumor cells of classical hodgkin lymphoma from anaplastic large cell lymphoma cells
Anaplastic large cell lymphoma ALK negative vs. peripheral T cell lymphoma (NOS) - diagnostic dilemma
Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma
T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma